A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe

(2021) Irina Cherniakov et al.   Clinical Pharmacology in Drug Development

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

(2021) Fumihiko Sakai et al.   HEADACHE

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

(2021) Fumihiko Sakai et al.   HEADACHE

Fremanezumab autoinjector pen for the prevention of migraine

(2021) Mark W Weatherall   Therapeutic Delivery

Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study

(2021) Fumihiko Sakai et al.   DRUG SAFETY

Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY

(2020) Peter J. Goadsby et al.   NEUROLOGY

Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18–45 years old

(2019) David L Gandell et al.   Patient Preference and Adherence

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review of Migraine Prophylaxis Adherence and Persistence

(2016) Zsolt Hepp et al.   JOURNAL OF MANAGED CARE PHARMACY

Improving Medication Adherence in Migraine Treatment

(2015) Elizabeth K. Seng et al.   Current Pain and Headache Reports

Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine

(2015) R. B. Lipton et al.   NEUROLOGY

Adherence to oral migraine-preventive medications among patients with chronic migraine

(2014) Zsolt Hepp et al.   CEPHALALGIA

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Prophylaxis of migraine: general principles and patient acceptance

(2011) Domenico D'Amico et al.   Neuropsychiatric Disease and Treatment

CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat

(2008) J Zeller et al.   BRITISH JOURNAL OF PHARMACOLOGY